Table 2 Comparison of mutation frequency across different public data (cBioPortal) and studies.
From: Mutation profiling of cancer drivers in Brazilian colorectal cancer
Gene | Present Study (n = 91) | TCGA (n = 224) | DFCI (n = 619) | Genentech (n = 72) | ICGC: COCA-CN (321) | Salem et al. (2413) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | |
APC | 65 | (71.4) | 168 | (75.0) | 361 | (58.3) | 29 | (40.3) | 173 | (53.9) | 1513 | (62.7) |
TP53 | 51 | (56.0) | 121 | (54.0) | 320 | (51.7) | 40 | (55.6) | 158 | (49.2) | 1641 | (68.0) |
KRAS | 48 | (52.7) | 94 | (42.0) | 173 | (27.9) | 37 | (51.4) | 118 | (36.8) | 1156 | (47.9) |
PIK3CA | 14 | (15.4) | 45 | (20.1) | 132 | (21.3) | 22 | (30.6) | 60 | (18.7) | 326 | (13.5) |
FBXW7 | 10 | (11.0) | 37 | (16.5) | 86 | (13.9) | 15 | (20.8) | 59 | (18.4) | — | — |
BRAF | 8 | (8.8) | 21 | (9.4) | 127 | (20.5) | 6 | (8.3) | 51 | (15.9) | 168 | (7.0) |
NF1 | 8 | (8.8) | 8 | (3.6) | 45 | (7.3) | 4 | (5.6) | 66 | (20.6) | — | — |
TGFBR2 | 8 | (8.8) | 23 | (10.3) | 29 | (4.7) | 2 | (2.8) | 25 | (7.8) | — | — |
BLM | 7 | (7.7) | 10 | (4.5) | 12 | (1.9) | 0 | (0.0) | 25 | (7.8) | — | — |
ATM | 6 | (6.6) | 25 | (11.2) | 64 | (10.3) | 13 | (18.1) | 53 | (16.5) | 34 | (1.4) |
MSH6 | 4 | (4.4) | 15 | (6.7) | 27 | (4.4) | 3 | (4.2) | 25 | (7.8) | — | — |
NRAS | 4 | (4.4) | 20 | (8.9) | 27 | (4.4) | 2 | (2.8) | 17 | (5.3) | — | — |
PTEN | 4 | (4.4) | 8 | (3.6) | 51 | (8.2) | 4 | (5.6) | 30 | (9.3) | 37 | (1.5) |
ERBB3 | 3 | (3.3) | 14 | (6.3) | 36 | (5.8) | 6 | (8.3) | 31 | (9.7) | — | — |
ERBB4 | 3 | (3.3) | 19 | (8.5) | 37 | (6.0) | 8 | (11.1) | 46 | (14.3) | — | — |
NOTCH1 | 3 | (3.3) | 0 | (0.0) | 65 | (10.5) | 6 | (8.3) | 38 | (11.8) | — | — |
CHEK2 | 3 | (3.3) | 1 | (0.4) | 36 | (5.8) | 5 | (6.9) | 22 | (6.9) | — | — |
NOTCH2 | 3 | (3.3) | 12 | (5.4) | 25 | (4.0) | 4 | (5.6) | 63 | (19.6) | — | — |
ROS1 | 3 | (3.3) | 13 | (5.8) | 31 | (5.0) | 2 | (2.8) | 46 | (14.3) | — | — |
STAT5B | 3 | (3.3) | 3 | (1.3) | 15 | (2.4) | 3 | (4.2) | 12 | (3.7) | — | — |
BRCA2 | 2 | (2.2) | 10 | (4.5) | 42 | (6.8) | 5 | (6.9) | 35 | (10.9) | — | — |
BRD2 | 2 | (2.2) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 16 | (5.0) | — | — |
EGFR | 2 | (2.2) | 10 | (4.5) | 28 | (4.5) | 4 | (5.6) | 53 | (16.5) | — | — |
JAK1 | 2 | (2.2) | 4 | (1.8) | 19 | (3.1) | 2 | (2.8) | 25 | (7.8) | — | — |
MAP2K4 | 2 | (2.2) | 11 | (4.9) | 13 | (2.1) | 2 | (2.8) | 16 | (5.0) | — | — |
MAP3K1 | 2 | (2.2) | 5 | (2.2) | 26 | (4.2) | 1 | (1.4) | 28 | (8.7) | — | — |
MTOR | 2 | (2.2) | 17 | (7.6) | 50 | (8.1) | 8 | (11.1) | 42 | (13.1) | — | — |
NBN | 2 | (2.2) | 2 | (0.9) | 20 | (3.2) | 1 | (1.4) | 26 | (8.1) | — | — |
